CY1119309T1 - Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας - Google Patents
Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιαςInfo
- Publication number
- CY1119309T1 CY1119309T1 CY20151101147T CY151101147T CY1119309T1 CY 1119309 T1 CY1119309 T1 CY 1119309T1 CY 20151101147 T CY20151101147 T CY 20151101147T CY 151101147 T CY151101147 T CY 151101147T CY 1119309 T1 CY1119309 T1 CY 1119309T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- ara
- leukemia
- naphthyridine
- cytochrome
- Prior art date
Links
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 title abstract 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title abstract 2
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 102100030497 Cytochrome c Human genes 0.000 title 1
- 108010075031 Cytochromes c Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 238000001815 biotherapy Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83523906P | 2006-08-02 | 2006-08-02 | |
| US87376006P | 2006-12-08 | 2006-12-08 | |
| PCT/US2007/017344 WO2008016702A2 (en) | 2006-08-02 | 2007-08-02 | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119309T1 true CY1119309T1 (el) | 2018-02-14 |
Family
ID=38859094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151101147T CY1119309T1 (el) | 2006-08-02 | 2015-12-15 | Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080063642A1 (enExample) |
| EP (2) | EP3025712A1 (enExample) |
| JP (4) | JP2009545601A (enExample) |
| CA (1) | CA2659861A1 (enExample) |
| CY (1) | CY1119309T1 (enExample) |
| DK (1) | DK2049109T3 (enExample) |
| ES (1) | ES2556677T3 (enExample) |
| HU (1) | HUE026693T2 (enExample) |
| MX (1) | MX344865B (enExample) |
| PL (1) | PL2049109T3 (enExample) |
| SI (1) | SI2049109T1 (enExample) |
| WO (1) | WO2008016702A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222622B2 (en) | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| MX2008015775A (es) * | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
| US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| AU2008317400B2 (en) | 2007-10-22 | 2014-10-02 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy |
| AU2008335772B2 (en) * | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| EP3284745A1 (en) | 2008-12-31 | 2018-02-21 | Sunesis Pharmaceuticals, Inc. | Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| US8470817B2 (en) * | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
| SMT202100234T1 (it) * | 2009-12-04 | 2021-05-07 | Oncoc4 Lnc | Usi di inibitori di fattori inducibili da ipossia |
| RU2550663C2 (ru) * | 2013-02-13 | 2015-05-10 | Владимир Владимирович Савостьянов | Способ гормонально-лучевой подготовки больных хроническим лимфолейкозом к последующей химиотерапии |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| EP3227338A4 (en) * | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| EP3297624B1 (en) | 2015-05-18 | 2021-03-03 | Syn-Nat Products Enterprise LLC | A pharmaceutical co-crystal and use thereof |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN108697093A (zh) * | 2015-06-19 | 2018-10-23 | 新纳特产品公司 | 含卡铂的组合物及其用途 |
| AU2016279099B2 (en) | 2015-06-19 | 2021-09-23 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| EP3297640A4 (en) | 2015-06-25 | 2019-01-02 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| WO2025033367A1 (ja) * | 2023-08-04 | 2025-02-13 | 湧永製薬株式会社 | 抗腫瘍剤併用療法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5382525A (en) * | 1992-11-27 | 1995-01-17 | American Air Liquide | Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| ATE209645T1 (de) | 1994-06-14 | 2001-12-15 | Dainippon Pharmaceutical Co | Neue verbindung, verfahren zu ihrer herstellung und antitumormittel |
| JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
| JP2001523977A (ja) * | 1997-06-05 | 2001-11-27 | ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ | Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子 |
| US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
| CA2363621A1 (en) * | 1999-02-26 | 2000-08-31 | The Johns Hopkins University | A novel inhibitor of programmed cell death |
| US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| AU2005222622B2 (en) * | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| US20050222267A1 (en) * | 2004-04-01 | 2005-10-06 | Truong Van H | Solution based methacholine formulations |
| US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| AU2006287149B2 (en) | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
-
2007
- 2007-08-02 US US11/890,196 patent/US20080063642A1/en not_active Abandoned
- 2007-08-02 JP JP2009522883A patent/JP2009545601A/ja active Pending
- 2007-08-02 DK DK07811049.1T patent/DK2049109T3/en active
- 2007-08-02 HU HUE07811049A patent/HUE026693T2/hu unknown
- 2007-08-02 MX MX2009001130A patent/MX344865B/es active IP Right Grant
- 2007-08-02 SI SI200731723T patent/SI2049109T1/sl unknown
- 2007-08-02 EP EP15189348.4A patent/EP3025712A1/en not_active Withdrawn
- 2007-08-02 EP EP07811049.1A patent/EP2049109B1/en not_active Revoked
- 2007-08-02 WO PCT/US2007/017344 patent/WO2008016702A2/en not_active Ceased
- 2007-08-02 CA CA002659861A patent/CA2659861A1/en not_active Abandoned
- 2007-08-02 PL PL07811049T patent/PL2049109T3/pl unknown
- 2007-08-02 ES ES07811049.1T patent/ES2556677T3/es active Active
-
2013
- 2013-09-25 JP JP2013198807A patent/JP2014040437A/ja active Pending
-
2014
- 2014-08-15 US US14/461,271 patent/US20150190380A1/en not_active Abandoned
-
2015
- 2015-11-09 JP JP2015219880A patent/JP6189911B2/ja not_active Expired - Fee Related
- 2015-12-15 CY CY20151101147T patent/CY1119309T1/el unknown
-
2016
- 2016-06-03 US US15/173,506 patent/US20170119745A1/en not_active Abandoned
-
2017
- 2017-08-03 JP JP2017150849A patent/JP2017226683A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HUE026693T2 (hu) | 2016-07-28 |
| JP6189911B2 (ja) | 2017-08-30 |
| EP2049109A2 (en) | 2009-04-22 |
| US20080063642A1 (en) | 2008-03-13 |
| DK2049109T3 (en) | 2016-01-11 |
| CA2659861A1 (en) | 2008-02-07 |
| ES2556677T3 (es) | 2016-01-19 |
| MX344865B (es) | 2016-12-19 |
| JP2009545601A (ja) | 2009-12-24 |
| PL2049109T3 (pl) | 2016-05-31 |
| EP2049109B1 (en) | 2015-11-18 |
| JP2017226683A (ja) | 2017-12-28 |
| MX2009001130A (es) | 2009-05-13 |
| US20170119745A1 (en) | 2017-05-04 |
| EP3025712A1 (en) | 2016-06-01 |
| WO2008016702A3 (en) | 2008-03-20 |
| SI2049109T1 (sl) | 2016-04-29 |
| WO2008016702A2 (en) | 2008-02-07 |
| US20150190380A1 (en) | 2015-07-09 |
| JP2016053070A (ja) | 2016-04-14 |
| JP2014040437A (ja) | 2014-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119309T1 (el) | Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας | |
| DE60318013D1 (de) | N-oxid von n-phenyl-2-pyrimidinaminderivaten | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| NO20074044L (no) | Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| TW200606162A (en) | Pyrazolopyridine derivatives | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| NO20064894L (no) | Beta-karboliner anvendbare for behandling av inflammatoriske sykdommer | |
| CY1109803T1 (el) | Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση | |
| NO20075508L (no) | Stannsoporfinpreparater og administrering | |
| AU2013219242C1 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer | |
| UA96742C2 (en) | Mek inhibitors and use thereof |